Document text
Principal Investigator: Allie Greenplate
Organization: MASSACHUSETTS GENERAL HOSPITAL
Fiscal Year: 2024
Award: $364,389
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary/Abstract
This CCHI U19 Program aims to determine how perturbations of the human immune system leads to do durable
changes that impact future immune responses. Core C of this Immune Perturbation Study Group Program
application will be central to the scientific efforts of this consortium. A unique and comprehensive pipeline has
been created alongside an expansive repository of existing samples and background data to measure and
analyze high dimensional immune landscapes using quantification of all circulating immune cell types with
activation status, serology and systemic inflammation over the course of different perturbations outlined in the
Projects. This pipeline will be maintained and expanded to include additional longitudinal samples from subjects
with post-acute sequalae of COVID-19 (Project 1), subjects cured of HCV (Project 2), and subjects receiving
vaccines during anti-PD-1 therapy (Project 3). This concerted effort will maintain high throughput of immune
phenotyping to catalyze scientific efforts across the consortium, including analyzing samples accrued by Core
B. Thus, Core C provides a central and integrative service that will allow studies in the different Projects to inter-
relate around immune landscapes during immune perturbation.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Acute><Antibodies><Antigens><Autoantibodies><Autoantigens><Autologous Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bar Codes><Blood><Blood Reticuloendothelial System><Blood Serum><Blood leukocyte><Burkitt Herpesvirus><Burkitt Lymphoma Virus><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CITE sequencing><CITE-seq><CITEseq><CMV><COVID-19 virus><COVID19 virus><Cell Body><Cells><Cellular Indexing of Transcriptomes and Epitopes by Sequencing><Cicatrix><Clinical><Clinical Treatment Moab><CoV-2><CoV2><Collection><Cytomegalovirus><Cytometry><Data><Data Analyses><Data Analysis><Data Reporting><Disease><Disorder><Drugs><EB virus><EBV><Environmental Factor><Environmental Risk Factor><Epstein Barr Virus><Event><Fluorescence><Foundations><Freeze Drying><Freeze Dryings><Freezing><Frequencies><Funding><Future><Germinal Center><Goals><Grant><Grippe><HCMV><HCV><HCV infection><HHV-4><HHV4><Hepatitis C><Hepatitis C virus><Hepatitis C virus infection><Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted><Hepatitus C><Heterogeneity><History><Human><Human Herpesvirus 4><Ig Somatic Hypermutation><Immune><Immune Monitoring><Immune mediated therapy><Immune response><Immune system><Immunes><Immunoglobulin Somatic Hypermutation><Immunologic Monitoring><Immunological Monitoring><Immunological response><Immunologically Directed Therapy><Immunomonitoring><Immunotherapy><Infection><Infectious Mononucleosis Virus><Influenza><Infrastructure><Intervention><Intervention Strategies><Leukocytes><Leukocytes Reticuloendothelial System><Libraries><Link><Lyophilization><Maps><Marrow leukocyte><Measurement><Measures><Medication><Mission><Modern Man><Monoclonal Antibodies><Multi-center studies><Multicenter Studies><Myeloid Cells><Network Analysis><Oligo><Oligonucleotides><PASC><PD-1 antibody therapy><PD-1 therapy><PD1 antibody therapy><PD1 based treatment><Pathway Analysis><Pathway interactions><Patients><Pharmaceutical Preparations><Phenotype><Population><Post Acute Sequelae of COVID19><Post Acute Sequelae of SARS-CoV-2><Post Acute Sequelae of SARS-CoV2><Post Acute Sequelae of severe acute respiratory syndrome coronavirus 2><Post-Acute Sequelae of SARS-CoV-2 Infection><Quality Control><RNA immunization><RNA vaccination><Recording of previous events><Reporting><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Gland Viruses><Sampling><Scars><Self-Antigens><Serology><Serum><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Shapes><Single cell seq><Specificity><Standardization><Structure of germinal center of lymph node><Study Subject><T Cell Specificity><T-Cell Immunologic Specificity><T8 Cells><T8 Lymphocytes><Testing><Time><Tube><Vaccination><Vaccines><Variant><Variation><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Wuhan coronavirus><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><adverse sequelae of COVID><adverse sequelae of COVID-19><adverse sequelae of coronavirus disease><adverse sequelae of coronavirus disease 2019><anti programmed cell death 1><anti-PD-1><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 therapy><anti-PD1 treatment><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 therapy><anti-viral antibody><antiPD-1><antiPD1><antigen-specific T cells><autoimmune antibody><autoreactive antibody><barcode><cell type><cellular indexing of transcriptomes and epitopes by single cell sequencing><chronic COVID-19 sequelae><chronic infection><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytokine><cytomegalovirus group><data infrastructure><data interpretation><data representation><data representations><deep learning based neural network><deep learning neural network><deep neural net><deep neural network><depository><drug/agent><environmental risk><fitness><flu><hCoV19><hep C><hepatitis non A non B><high dimensionality><histories><host response><immune health><immune system health><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoresponse><infection by hepatitis c virus><inflammatory environment><inflammatory milieu><interventional strategy><long haul sequelae of COVID-19><long haul sequelae of coronavirus disease 2019><long-term sequelae of COVID-19><long-term sequelae of SARS-CoV-2><long-term sequelae of coronavirus disease 2019><long-term sequelae of severe acute respiratory syndrome coronavirus 2><mAbs><mRNA immunization><mRNA vaccination><monoclonal Abs><nCoV2><non A, non B hepatitis><non-A, non-B hepatitis><non-genetic><nongenetic><oligos><pathway><persistent infection><post COVID-19 sequelae><post acute sequelae following COVID-19><post-acute sequelae following SARS-CoV-2 infection><post-acute sequelae of COVID-19><post-acute sequelae of acute COVID infection><post-acute sequelae of coronavirus disease 2019><programmed cell death protein 1 therapy><programs><receptor binding><receptor bound><recurrent neural network><repository><response><self reactive antibody><single cell analysis><single cell next generation sequencing><single cell sequencing><somatic hypermutation><statistics><systemic inflammation><systemic inflammatory response><vaccination study><vaccination trial><vaccine antibodies><vaccine induced antibodies><vaccine study><vaccine trial><vaccine-induced antibodies><viral infection><virus infection><virus-induced disease><white blood cell><white blood corpuscle><αPD-1><αPD1>